Alnylam Pharmaceuticals has been subject to numerous business undertakings, partnerships, and financial updates. The firm's collaboration with
Viz.ai for cardiac amyloidosis detection made noteworthy news, demonstrating strategic growth in digital health. Their partnership with
Tenaya for cardiovascular disease therapeutic target discovery was also notable. Additional partnerships, such as the one with the
Alliance for Genomic Discovery to expand clinical genomic datasets, further showcase their innovative drive. Financial assessments indicate a strong growth trajectory, with Alnylam's sales increasing by 151% through the TTR franchise, inspiring a projected 2026 revenue of around $5.3 billion. Alnylam continues to strengthen its financial portfolio, despite lingering concerns over key drug sales projections. An ambitious five-year plan charts the way forward for the company, coupled with $250 million investment in manufacturing and q4 results that surpassed expectations, strengthened investor confidence. However, challenges in the TTR space and few late-stage catalysts remain a concern.
Alnylam Pharmaceuticals News Analytics from Thu, 18 Sep 2025 07:00:00 GMT to Sat, 04 Apr 2026 07:25:54 GMT -
Rating 8
- Innovation 8
- Information 9
- Rumor 7
